Cite
HARVARD Citation
Eichenauer, D. et al. (2022). Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Hematological oncology. 40 (4), pp. 801-804. [Online].